New development of oHSV for cancer treatment
Sponsored by: Open Therapeutics™

Abstract:

Sponsored by Open Therapeutics. Matching funds are being sought. Details coming soon...


This grant will award up to $3,000.00 towards the winning proposal(s).

Proposals that utilize the following Technologies will be considered: oncolytic herpes simplex virus (oHSV)-rQT3 against cancer cells

Voting Period:

From 2018-09-01 22:00 UTC to 2018-10-01 22:00 UTC